Abstract
Bone quality has been seen as an important concept which refers to microarchitecture, bone turnover, micro-damage accumulation, and mineralization because there is no strong correlation between the increase of bone mineral density and the fracture risk reduction. Intermittent administration of parathyroid hormone (PTH) stimulates bone formation, and continuous infusion of PTH stimulates bone resorption. In the preclinical studies, intermittent administration of PTH increased bone strength in association with the increase in total body skeletal mass and the improvement of bone structure. Furthermore, the clinical studies showed that PTH improved bone structure such as trabecular connectivity and cortical thickness, as well as increased bone mass. These changes were considered to contribute to reduction of fracture risk.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call